ADReCS

Pharmaceutical Information

Drug Name	Isoniazid
Drug ID	BADD_D01204
Description	Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage	For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status	approved; investigational
ATC Code	J04AC01
DrugBank ID	DB00951
KEGG ID	D00346
MeSH ID	D007538
PubChem ID	3767
TTD Drug ID	D09XQF
NDC Product Code	60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII	V83O1VOZ8L
Synonyms	Isoniazid \| Isonicotinic Acid Hydrazide \| Hydrazide, Isonicotinic Acid \| Phthivazide \| Phthivazid \| Isonicotinic Acid Vanillylidenehydrazide \| Acid Vanillylidenehydrazide, Isonicotinic \| Vanillylidenehydrazide, Isonicotinic Acid \| Ftivazide \| Tubazide \| Isonex

Chemical Information

Molecular Formula	C6H7N3O
CAS Registry Number	54-85-3
SMILES	C1=CN=CC=C1C(=O)NN
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Tinnitus	04.04.01.002; 17.04.07.004	-	-
Toxic encephalopathy	12.03.01.027; 17.13.01.004	0.005560%		-
Toxic epidermal necrolysis	10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008	0.018068%
Trismus	15.05.04.004; 17.01.03.004	0.002780%
Unresponsive to stimuli	17.02.05.031	0.002780%		-
Urinary incontinence	17.05.01.008; 20.02.02.010	0.002780%
Urticaria	10.01.06.001; 23.04.02.001	-	-
Vascular headache	17.14.01.005; 24.03.05.007	-	-	-
Vasculitis	10.02.02.006; 24.12.04.027	0.002780%
Vasculitis necrotising	10.02.02.008; 24.12.04.029	0.005560%		-
Vertigo	04.04.01.003; 17.02.12.002	-	-
Visual impairment	06.02.10.013	0.006949%		-
Vitamin B6 deficiency	14.12.02.005	0.006949%		-
Vitamin D deficiency	14.12.03.003	0.002780%		-
Vomiting	07.01.07.003	0.060321%
Wheezing	22.03.01.009	0.004170%
Mental status changes	19.07.01.001	0.006949%		-
Tubulointerstitial nephritis	20.05.02.002	0.008339%		-
Postictal state	17.02.04.014; 19.13.01.005	0.002780%		-
Acute generalised exanthematous pustulosis	10.01.01.034; 11.07.01.018; 12.03.01.005; 23.03.10.002	0.002780%		-
Paradoxical drug reaction	08.06.01.014	0.011119%		-
Brain oedema	12.01.10.010; 17.07.02.003	0.008339%
Emotional distress	19.04.02.008	-	-	-
General physical health deterioration	08.01.03.018	0.005560%		-
Lupus-like syndrome	10.04.03.003; 15.06.02.004; 23.03.02.004	0.009729%		-
Haemodynamic instability	24.03.02.006	0.002780%		-
Fanconi syndrome acquired	14.01.01.013; 20.05.03.012	0.002780%		-
Epigastric discomfort	07.01.02.004	-	-	-
Inappropriate antidiuretic hormone secretion	05.03.03.001; 14.05.07.001	0.004170%		-
Skin burning sensation	17.02.06.009; 23.03.03.021	-	-	-

The 9th Page First Pre 9 10 11 Next Last Total 11 Pages